Designed With Patients In Mind

Share / Send / Save

On-demand therapy in their hands

FIRAZYR is the first and only self-injectable, subcutaneous therapy for patients 18 years and older that treats acute attacks of HAE. Patients can self-administer FIRAZYR after being trained by a healthcare professional.1

Powerful and portable acute HAE therapy

Supplied in a 3 mL, prefilled, self-injectable, single-use syringe (30 mg)1

Requires no reconstitution, dose calculation, dose titration or refrigeration. Store FIRAZYR between 36°F and 77°F (2°C and 25°C).1

FIRAZYR® (icatibant injection) product image

According to data collected for 230 patients, FIRAZYR self-administration may reduce the time to treatment initiation during an acute HAE attack2

FIRAZYR directly blocks the activity of bradykinin1

  • FIRAZYR blocks bradykinin from binding the BK2 receptor, thereby treating the clinical symptoms of an acute HAE attack.3

In hand. On demand.

  • Patients can promptly self-administer FIRAZYR upon recognition of symptoms of acute HAE attacks, after being trained by a healthcare professional. Note: Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately, in addition to treatment with FIRAZYR.1
  • The recommended dose of FIRAZYR is 30 mg administered as a slow, subcutaneous injection, given over at least 30 seconds, into the abdominal area.1
  • If response is inadequate or if symptoms recur, additional doses may be administered at intervals of at least 6 hours. No more than 3 doses may be administered in any 24 hour period.1